![FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory B-Cell Lymphoma](https://oncodaily.com/pub/uploads/2023/05/Epkinly-Genmab-AbbVie-1720x1146-1-1280x853.jpg)
Photo: Cancer Therapy Advisor
May 24, 2023, 15:29
FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory B-Cell Lymphoma
In an article published by The ASCO Post, it states that “May 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the bispecific CD20-directed CD3 T-cell engager epcoritamab-bysp (Epkinly) for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.”
Source: The ASCO Post